Dataset from A Phase III Safety Study of Pro-NETU in Patients Receiving Highly Emetogenic Chemotherapy (Doxorubicin/Epirubicin and Cyclophosphamide): CONSOLE-BC

This is a multicenter, randomized, double-blind, phase 3 study to examine the safety of single intravenously administration of Pro-NETU in combination with palonosetron and dexamethasone in patients receiving doxorubicin/cyclophosphamide (AC) or epirubicin/cyclophosphamide (EC) based HEC. For more information, visit: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.34088